Atara Biotherapeutics Announces $15 Million Registered Direct Offering
January 08, 2024 09:00 AM Eastern Standard Time THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients…